-+ 0.00%
-+ 0.00%
-+ 0.00%

Rainmed FY26 H1 loss attributable to shareholders narrows 31.7% to RMB 22 million; revenue rises 41.3% to RMB 14.7 million

PUBT·08/31/2026 10:00:04
Listen to the news
Rainmed FY26 H1 loss attributable to shareholders narrows 31.7% to RMB 22 million; revenue rises 41.3% to RMB 14.7 million
  • Rainmed Medical posted revenue of RMB 14.7 million for the six months ended June 30, 2026, up 41.3%.
  • Gross profit more than doubled to RMB 9.3 million, lifting gross margin to 63.2%, up 14 percentage points.
  • Loss attributable to shareholders narrowed to RMB 22 million; basic and diluted loss per share improved to RMB 0.02.
  • Results reflected higher FlashPressure caFFR pressure transducer sales; coronary artery cutting balloon added RMB 1.39 million in revenue.
  • Network reached 141 domestic distributors covering 291 hospitals; interim dividend was not declared.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rainmed Medical Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12308592), on August 31, 2026, and is solely responsible for the information contained therein.